Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.56 |
| ▸ | BRD2 | P25440 | 2/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732062 | 0.87 | BRD4 (0.69) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL13731571 | 0.87 | BRD4 (0.56) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619143 | 0.87 | BRD4 (0.54) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619060 | 0.87 | BRD4 (0.54) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619573 | 0.87 | BRD4 (0.54) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619461 | 0.86 | BRD4 (0.64) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16774314 | 0.81 | BRD4 (0.58) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967453 | 0.80 | BRD4 (0.50) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL15972881 | 0.79 | LMNA (0.50) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967397 | 0.79 | BRD4 (0.50) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699573-B1 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2699573-B1 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2699573-A2 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | GLAXOSMITHKLINE LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | GLAXOSMITHKLINE LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | GLAXOSMITHKLINE LLC (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012143416-A2 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7, UGT1A7 | BRD4 5/4885CYP3A4 45/4885CYP2C9 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.